Novo Nordisk Hopes To Gradually Build US Access To Obesity Therapy
Executive Summary
With US FDA approval of Wegovy for obesity, Novo Nordisk prices the weekly injectable at par with its other obesity brand Saxenda. Ramping up sales will require patient, clinician and payer education, the company says.
You may also be interested in...
Obesity Market Potential Is Huge, But Access To Drugs An Increasing Challenge
Despite double-digit weight loss across several drugs presented at ADA, experts note access to obesity therapies will be constrained without outcomes data to justify their widespread use and cost.
With Competition Closing In, Novo Details Oral Semaglutide Weight Loss At ADA
Novo’s oral semaglutide generated 15.1% weight loss at 68 weeks in the Phase IIIa OASIS 1 study, but Lilly’s orforglipron provided up to 14.7% weight loss at 36 weeks in Phase II without reaching a plateau.
Tirzepatide’s Glowing Obesity Data Steal Show On Lilly’s Earnings Call
Tirzepatide shows ability to produce a mean 52-pound weight loss at 72 weeks, setting up a market showdown with Novo’s Wegovy. Lilly’s quarterly call included reassurance about donanemab for Alzheimer’s and high growth for its COVID-19 antibody.